



VIRTUAL ANNUAL  
SCIENTIFIC MEETING



GOING HEAD TO HEAD AGAINST  
**HEADACHE**  
THE AMERICAN HEADACHE SOCIETY®

JUNE 3-6  
2021

## 2021 Virtual Annual Scientific Meeting On Demand Poster Presentations by Category

### Basic Science

Safety Evaluation of Fremanezumab in Nonclinical Developmental and Reproductive Toxicology (DART) Studies in Rats and Rabbits

Maya Sokolovsky, MSc

### Clinical Presentation/Diagnosis

Expert Consensus on the Benefits and Limitations of the Diagnostic Criteria for Post-Traumatic Headache as Defined by the International Classification of Headache Disorders-3rd Edition

Emily Schlitz-Fortenberry, MD  
Erafat Rehim, MD

Overt Ergotism Due to Overuse of Ergotamine-caffeine  
Neuroocular Migraine\*

*\*Not CME Eligible*

FRANCIS M V, MBBS, MS

Sharp Edge Eye Syndrome (SEES): A Survey of Self-identified Individuals

Merrick Reynolds

Nutcracker Phenomenon with Headache as the Predominant Symptom: A Unique New Daily Persistent Headache Subtype?

Todd Rozen, MD

Paroxysmal Hemicrania: Case Series Presenting in an Orofacial Pain Clinic

Anas Al-Tae, DDS

Pachymeningeal Enhancement in an Atypical Presentation of Giant Cell Arteritis

Ayesha Ahmad, MD

Childhood Variant Intermittent Angle Closure: A Treatable Pediatric Headache of Ophthalmic Etiology

Grant Slagle, DO  
Michael Yang, MD

New Onset Cluster Headache, Triggered by COVID?

The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study Using Daily Prospective Diary Data\*

*\*Not CME Eligible*

Serena Orr, MD, MSc  
Matthew Kozminski, DO, FAHS

Cervical Dystonia Associated with Post-Traumatic Chronic Migraine  
Important Factors Associated with Hesitating to Consult for Migraine Care: Results of the OVERCOME (US) Study

Michael Reed, PhD

Allodynia and Headache Related to Personal Protective Equipment to Prevent COVID-19

Karen Ferreira, PhD

The Role of a Potential Biomarker in Patients with Migraine: Review and New Insights

Karen Ferreira, PhD

Traumatic Brain Injury Temporal Lesion Causing Hemicrania Continua: A Case Report

Caitlin Christensen, MD

Relation Between Central Sensitization and Temporomandibular Disorder

Alinne Rymovicz, PhD

Questionnaire-based Evaluation of Sleep Quality in Patients with Migraine- a Case-control Study	Rahul Sabharwal, MBBS
Interdisciplinary Care for a Refractory Vestibular Migraine Patient Through Same-day Visits with Headache Neurology, Physical Therapy, Occupational Therapy, and Pain Psychology	Shivani Shah, DO
Delayed Secondary Intracranial Hypertension Post Mild Traumatic Brain Injury	Lauren Green, DO
COVID-19 Related Headache Exquisite Response to Therapy	Anvita Suneja
Single-centre Experience of Headache Phenotype in Children with Idiopathic Intracranial Hypertension	Hiba Akbari, MBBS
Interictal Light Sensitivity in Migraineurs with Aura vs Without Aura	Cecilia Martindale
Clinical, Psychological, and Sensory Characteristics Associated with Headache Attributable to Temporomandibular Disorder in Participants with Chronic Myofascial Temporomandibular Disorder	Inna Tchivileva, MD, MS
Episodic Status Migrainosus: A Cross Sectional Study	Mauricio Rueda-Sánchez, MD
Stabbing Headache Associated with Thalamic Hemorrhage: A Case Report	Anam Baig, DO
A History of Mild Traumatic Brain Injury Is Associated with Disability and Severity of Migraine	Ryotaro Ishii, MD, PhD
Clinical Course of Migraine During Strict Quarantine Due to SARS-Cov-2: Effect of Psychiatric Comorbidities in a Clinical Cohort	Joe Munoz-Ceron
Lack of Effect of TBI-related Factors on Headache Occurrence in Veterans 2-15 Years After Deployment-related TBI	James Couch, MD, PhD
Rhinologist Referral to a Headache Specialist for Non-Sinogenic Headache : A Fast Track Approach to an Interdisciplinary Collaboration	Jyotika Singh, Do
Comorbidity of Patients with Dementia and Migraine in a Large Tertiary Academic Center	Mason Dyess, DO
High Normal and Elevated Opening Pressures Predict Headache Improvement After Cerebrospinal Fluid Withdrawal	Andrew Martin, MD
Hemiplegic Migraine Triggered by a Bomb Cyclone Misdiagnosed as Stroke: A Case Series	Courtney Iser, MD
Identification of Patients with Migraine, Migraine-Related Symptoms and Migraine Medication Use Within Electronic Medical Records Using Artificial Intelligence*	Steven Kymes, PhD, MHA
<i>*Not CME Eligible</i>	
A Rare Case of Unilateral Facial Weakness Secondary to Perimesencephalic Non-aneurysmal Sub-arachnoid Haemorrhage!*	Nishanth Rajanna
<i>*Not CME Eligible</i>	
Relationship Between Intervals of the Menstrual Cycle and Presentation to the Emergency Department for Headache	Crystal Jicha, MD
Dialysis- Triggered Cluster Headache: A Case Report	Shivani Shah, DO
New Daily Persistent Headache Associated with Trisulfated Heparin Disaccharide (TS-HDS) Antibody: A Case Report	Shivani Shah, DO
Case Report: COVID-19 Nasopharyngeal Swab Test Triggering Migraines	Aarushi Suneja, MD
Habitus and the Brain in Pain: Influence of BMI on Migraine Patients Seen at a Large Tertiary Headache Center	Natalia Murinova, MD
When a Peleton Ride Leads to a Nonaneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Case Study	Nicholas Koroneos, DO
Dysautonomic Manifestations in Migraine, Tension-type Headache and Cranial Neuralgias. Results from PREMECEF	Luis Fernández-Garza

Post COVID-19 Headache: A Mexican Online Survey	Luis Fernández-Garza
The Caffeinated Brain in Pain: Caffeine Use in Migraine Patients at a Large Tertiary Headache Center	Natalia Murinova, MD
Educated Brain in Pain: The Influence of Education Level on Migraine Patients Seen at a Large Tertiary Headache Center	Natalia Murinova, MD
Headache Associated with Personal Protective Equipment in Healthcare Workers During COVID-19 Outbreak in a Referral Centre in Mexico*	
<i>*Not CME Eligible</i>	Rogelio Dominguez-Moreno
Vegetable, Fruits, and the Brain in Pain: Quantification of Nutrition in Migraine Patients at a Large Tertiary Headache Center	Natalia Murinova, MD
Case Series of Headache in Children and Adolescents with COVID-19*	
<i>*Not CME Eligible</i>	Rebecca Barmherzig, MD
RED EAR SYNDROME AND MIGRAINE: sign or syndrome?	Isabel Luzeiro, MD
The role of Endolymphatic Hydrops in differentiating Vestibular Migraine from Ménière's Disease	Isabel Luzeiro, MD
Vestibular migraine in children: clinical characterization of a cohort	Isabel Luzeiro, MD

## Epidemiology

Comorbidity of Temporomandibular Disorders in Migraine and Tension-type Headache Patients: A Systematic Review with Meta-analysis of Observational Studies	Paolo Bizzarri, PhD
Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data from a Phase 3 Clinical Trial (ADVANCE) in Patients with Episodic Migraine*	
<i>*Not CME Eligible</i>	Richard Lipton, MD
Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine*	
<i>*Not CME Eligible</i>	Richard Lipton, MD
Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine*	
<i>*Not CME Eligible</i>	Pranav Gandhi, PhD
Predicting Treatment-response to Prescription Acute Migraine Medications	Ali Ezzati, MD
Migraine Synonyms - A 5 Year Study*	
<i>*Not CME Eligible</i>	FRANCIS M V, MBBS, MS
Migraine and Tension-Type Headache Among Children and Adolescents: Application of International Headache Society Criteria in a Clinical Setting	Jacob Genizi, MD
Cerebral Venous Thrombosis (CVT) Associated with Covid 19 Infection; A Multi- center Study	Sajid Hameed Shaikh, MBBS, FCPS
Prevalence and Impact of Visual Aura in Migraine: A Population-based Study	Min Kyung Chu, MD, PhD
Circadian misalignment and average headache frequency and severity in a cohort of adults with episodic migraine in Greater Boston	Kobina Hagan, MBChB, MPH

## Genetics

CACNA1A Mutation in Complex Patient with Hemiplegic Migraine and Bilateral Basal Ganglia Calcifications

Paul Gong, MD

## Headache Education

American Headache Society National Headache Fellowship Opportunities Website Performance Review

Niushen Zhang, MD

Refractory Chronic Migraines in Patients with Mast Cell Activation Syndrome

Ana Gjurgevich, MSN

Measuring the Efficiency of an Online Migraine Management Course in Expanding Education Among Medical Professionals

Frederick Godley, MD

The State of Headache Medicine Education in North America: An Observational, Survey-based Study of Neurology Clerkship Directors and Curriculum Deans

Anna Pace, MD

Migraine and Other Primary Headache Diagnoses and Treatment- a Knowledge and Needs Assessment of Physical Therapists

Danielle Messier, MSPT, DPT, Cert MDT

Impact of the Vega Healthcare Provider Report on Provider Satisfaction and Decision-making Confidence in Simulated Patient Portal Visits for Migraine

Paul Rizzoli, MD

Lasmiditan Is Effective in the Acute Treatment of Migraine in Patients with Insufficient Response to Triptans: Findings from the CENTURION Study\*

*\*Not CME Eligible*

John Krege, MD

Does Wearing off of Efficacy Occur in Galcanezumab-treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials

Jessica Ailani, MD

Episodic and Chronic Cluster Headache: Evaluation of Health-related Quality of Life Impact and Estimation of Health-state Utilities\*

*\*Not CME Eligible*

Antje Tockhorn-Heidenreich, MSc

Evaluation of Cardiovascular Risks in Patients Treated with Longer-term Exposure to Galcanezumab

Richard Kovacs, MD

Knowledge and Needs of Pain Medicine Providers in Migraine Management

Jackie Yang, BS

Telehealth Headache Simulation for Nurse Practitioner Students During the COVID-19 Pandemic

Calli Cook, DNP

A Dedicated Headache Medicine Elective for Third and Fourth Year Medical Students\*

*\*Not CME Eligible*

Alina Masters-Israilov, MD

The Effect of Undergraduate Education on Headache at a Japanese Medical School: A Survey of Student Experience and Confidence

Yasushi Shibata, MD, PhD

## Health Services/Outcomes Research

The Impact of the COVID-19 Pandemic on Patients with Migraine and Other Headache Disorders

Rachel Lu

Correlates of Migraine Treatment Satisfaction in a High Frequency Sample: Results from the Coalition for Headache and Migraine Patients' (CHAMP) Headache Disease Patient Access Survey\*

*\*Not CME Eligible*

Caroline Brooks, MA

What Role Do Urgent Care Centers Play in Headache Management? A Quality Improvement Study of Select Urgent Care Facilities

Dennique Khanns

The Effects of COVID-19 on Access to Telemedicine Visits in a Tertiary Headache Clinic	Aarushi Suneja, MD
Telehealth as a New Care Delivery Model: The Headache Provider Experience*	Mia Minen, MD, MPH
<i>*Not CME Eligible</i>	
Impact of and Response to the COVID-19 Pandemic on Headache Care Delivery Within the Veterans Health Administration: A National Cohort Study	Jason Sico, MD, MHS
Impact of and Response to the COVID-19 Pandemic on Headache Care Delivery Within the Veterans Health Administration: A National Cohort Study	Jason Sico, MD, MHS
Annual Indirect Cost Savings in Patients with Episodic or Chronic Migraine: Post-hoc Analyses from Multiple Galcanezumab Clinical Trials*	Joshua Tobin, MD, FAHS
<i>*Not CME Eligible</i>	
Comparative Study of Transcranial Doppler Parameters and Vasomotor Reactivity in People with IHH versus People with Migraine and Normal Population	Vikas Lakhanpal, MD
Optimal Acute Treatment Is Associated with Productivity Gains in People with Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study	Dawn Buse, PhD
Characteristics, Healthcare Utilization, and Comorbidities of People with Medically Diagnosed Migraine in the Veteran's Health Administration: A National Cohort Study, 2008-2019	Elizabeth Seng, PhD
Study of Prescription Practices, Causes of Referral and Delay in Diagnosis of Headache by General Practitioners: A Cross-sectional Study	Sulabh Tiwari, MD
Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results from the CaMEO Study*	Dawn Buse, PhD
<i>*Not CME Eligible</i>	
Rimegepant 75 Mg, Ubrogapant, and Lasmiditan in the Acute Treatment of Migraine Applying the Benefit-Risk Method of Likelihood of Being Helped or Harmed	Karissa Johnston, PhD
What Are Essential Components of Care in a Headache Center? Perspectives from Headache Neurologists	Roberta Goldman, PhD
Single Center Experience of MAbs-CGRP Use for Migraine Prevention*	Christopher Bondoc, MD
<i>*Not CME Eligible</i>	
Switching Associated with Initiation of Calcitonin Gene-Related Peptide Monoclonal Antibodies versus Non-Calcitonin Gene-Related Peptide Monoclonal Antibodies Treatments for Prevention of Migraine*	Richard Wenzel, PharmD
<i>*Not CME Eligible</i>	
Leveraging Telemedicine to Improve Access to Evidence-Based Headache Care*	Sara Crystal, MD
<i>*Not CME Eligible</i>	
Real-World Safety and Efficacy of 155-195U OnabotulinumtoxinA in Participants with Chronic Migraine: Results from the REPOSE Study*	Katherine Sommer, PhD
<i>*Not CME Eligible</i>	
Functional REstoration with rEyvow (FREE): A US-based Cross-sectional Survey in Patients Taking Lasmiditan*	Carrie Dougherty, MD, FAHS
<i>*Not CME Eligible</i>	
Who Receives Novel Acute Treatments for Migraine?*	Gerhardt Pohl MS, PhD
<i>*Not CME Eligible</i>	

Adherence and Persistence Associated with Calcitonin Gene-Related Peptide Monoclonal Antibodies Compared to Non-Calcitonin Gene-Related Peptide Monoclonal Antibodies Treatments for Prevention of Migraine*	Janet Ford, MPH, PhD
<i>*Not CME Eligible</i>	
Identification of High-cost Triptan and Ergotamine-based Acute Therapies Used for Migraine in Medicaid 2019*	Thomas O'Connell, MA
<i>*Not CME Eligible</i>	
Assessing the Comparative Efficacy of INP104 for Acute Treatment of Migraine Attacks: A Matching-adjusted Indirect Comparison Primary Headache Disorders and Acute Medications Associated with Patients Diagnosed with Medication Overuse Headache: Analysis of US Claims Data*	Shivang Joshi, MD, MPH, RPh
<i>*Not CME Eligible</i>	
Real-world Data on Reductions in Migraine and Headache Days with Fremanezumab Treatment for US Patients with Chronic and Episodic Migraine: Results from a Physician Chart Review Study*	Andrew Ahn, MD, PhD
<i>*Not CME Eligible</i>	
Real-world Data on Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in US Adult Patients with Migraine: Results from a Physician Chart Review Study*	Joshua Cohen, MD, MPH, FAHS
<i>*Not CME Eligible</i>	
Real-world Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab Treatment: A US Retrospective Claims Analysis*	Joshua Cohen, MD, MPH, FAHS
<i>*Not CME Eligible</i>	
Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: A US Retrospective Claims Analysis	Dawn Buse, PhD
Real-World Impact of AJOVY Use on Clinical Outcomes Among Migraine Patients with Comorbid Depression, Anxiety or Hypertension*	Dawn Buse, PhD
<i>*Not CME Eligible</i>	
Patient Preferences for Self-injectable Preventive Treatments for Migraine*	Krishna Tangirala, PhD
<i>*Not CME Eligible</i>	
Treatment Experiences in a High Frequency Sample of People with Migraine: Results of the Coalition for Headache and Migraine Patients (CHAMP) Headache Disease Patient Access Survey	Jaein Seo, PharmD, MHS
Dihydroergotamine Infusion for Pediatric Refractory Headache Disparity Between Self-Reported and Functional Disability Among Adults with Migraine	Beth Morton, PhD Rasha Srouji, DNP, CPNP, CNRN
Migraine Treatment in Pregnancy- a Knowledge and Needs Assessment of Women's Health Care Providers	Robert Shapiro, MD, PhD
Impact of the COVID-19 Pandemic on People Living with Migraine: Results of the MICOAS Qualitative Study*	Brian M. Grosberg, MD, FAHS
<i>*Not CME Eligible</i>	
Calcitonin Gene-related Peptide (CGRP) Monoclonal Antibody (MAB) Wear-off Phenomenon in the Treatment of Migraine	Dawn Buse, PhD
Assessing Resident Opinions and Usage of Quality Measures for Headache Patients in the Resident Continuity Clinic*	Maria E. Garcia-Ayala, MD
<i>*Not CME Eligible</i>	
Acute and Preventive Treatment Priorities Among Persons Living with Migraine: Results of the MiCOAS Qualitative Study	Aakash Bhargava, MD Maya Gerstein, DRPH

Feasibility and Efficacy of Telemedicine in Patients with Chronic Headache in a Developing Country During the COVID-19 Pandemic: A Prospective Cohort Study

Real-World Outcomes of Eptinezumab

CME-certified Patient-Physician Vignette Increased Awareness of Risk Factors for Migraine Chronification and the Appropriate Use of Preventive Therapies Among Neurologists and PCPs\*

*\*Not CME Eligible*

Impact of Online-Delivered Headache Education on Community based Pediatricians' Confidence in managing Primary Recurrent Headache

Locating Organizations and Their Methods in Registrations of Clinical Migraine Trials: Analysis of ClinicalTrials.gov

Migraine Management with Telemedicine Visits Only: Can Patients Achieve Clinically Meaningful Improvement?\*

*\*Not CME Eligible*

Tertiary care headache services embedded in a primary care underserved setting in Boston, MA: establishment and early experiences

Sucharita Ray, MD  
Anam Baig, DO

Thomas Finnegan, PhD  
Marielle Kabbouche Samaha, MD

Pengfei Zhang, MD

Brad Torphy, MD

Angeliki Vgontzas, MD

## Imaging and Neurophysiology

A Computational Model Explores the Regulation of Cerebrospinal Fluid and Brain Tissue Sodium Levels During Migraine

Clinical Correlates of Cross-Sectional and Longitudinal Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients

Cerebral Hemodynamics with Migraine Onset and Intervention

Bruno Jacob, BSc, MSc

Roberta Messina, MD  
Samuel Grant, PhD

## Other

The Visual Quality of Life in Patients with Photophobia  
Physician-Assistance Algorithm for Migraine Medications

Considerations for Treatment of Comorbid Headaches and Mast Cell Activation Syndrome: A Multidisciplinary Team Approach

Economic Modeling of Migraine Prevention Therapies: Considerations for Current and Emerging Therapies

Novel Acute Therapies in the Treatment of Migraine: Impact of Re-dosing on Cost-utility Outcomes

Refractory Migraine Treatment During Pregnancy: A Case Report

Amanda Redfern, MD  
Pengfei Zhang, MD

Lindsey Reeves, DO

Karissa Johnston, PhD

Karissa Johnston, PhD  
Chelsea Stone, DO, MA

Utilization and Perceptions of Telehealth Headache Services in the Veterans Health Administration Headache Centers of Excellence Prior to and During the COVID-19 Pandemic: A Mixed Methods Study

The Psychologists' Role in Pediatric and Adult Headache Care: A Qualitative Analysis with Seven Experts

Amy Grinberg, PhD

Amy Grinberg, PhD

Experiences of an Academic Headache Center with Telehealth for Headache Pain Psychology Treatment During the Covid-19 Pandemic  
Stroke risk in perimenopausal women with migraine

Susan Axtell, PsyD  
Crystal Sosa, MD

## Other Clinical Studies

Efficacy and Safety of Intravenous Sodium Valproate in Pediatric Patients with Refractory Chronic Headache Disorders: A Retrospective Review	Sara Pavitt, MD
Crowdsourcing Post-marketing Safety Surveillance for Migraine Preventives: Self-reported Adverse Events Associated with Calcitonin Gene-related Peptide (CGRP) Therapeutics on a Social Media Forum* <i>*Not CME Eligible</i>	Pengfei Zhang, MD
Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Coadministered with Esomeprazole Magnesium* <i>*Not CME Eligible</i>	Ramesh Boinpally, PhD
A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results from the ACHIEVE I and ACHIEVE II Trials* <i>*Not CME Eligible</i>	Aubrey Manack Adams, PhD
A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results from the ACHIEVE I and ACHIEVE II Trials	Charlie Iaconangelo, MS, PhD
Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine	Jelena M. Pavlovic, MD, PhD Thomas Mathew, MD, DM
Essential Oils and Cluster Headache: Insights from Two Cases	
A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1 Hour Post-dose in the Pooled ACHIEVE I and ACHIEVE II Trials* <i>*Not CME Eligible</i>	Aubrey Manack Adams, PhD
Long-term Safety and Tolerability of Atogepant Following Once Daily Dosing over 1 Year for the Preventive Treatment of Migraine* <i>*Not CME Eligible</i>	Lawrence Severt, MD, PhD
Atogepant 60 Mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results from a 52-Week Open-Label Extension Trial* <i>*Not CME Eligible</i>	Andrew Blumenfeld, MD Carmelo Tiberio Currò, MD
Chronic Migraine and Alimentation During COVID-19 Lockdown "Migraine Burden Index": A New Instrument for Assessing Migraine-Related Clinical Disability* <i>*Not CME Eligible</i>	Allison Koutsandreas, CANP
Prodromal and Postdromal Symptoms in Primary Headaches. PREMECEF Results	Luis Fernández-Garza William Qubty, MD
Melatonin for Pediatric Migraine Prevention	
Exercised Brain in Pain, Quantification of Exercise in Migraine Patients Seen at a Large Tertiary Headache Center	Mason Dyess, DO
Napping and headache outcomes in adults with episodic migraine: a six-week prospective cohort study	Angeliki Vgontzas, MD

## Therapeutics

The Outpatient Pharmacologic Management of Status Migrainosus in Adults: Systematic Review and Expert Opinion, a Need of the Hour	Sankeerth Challagundla, MD
Physician Assessment of Patients' COVID-19 Risk and Impact on Lasmiditan, Ubrogepant, or Rimegepant Prescription Decisions: Analysis from a Cross-Sectional, Retrospective US Patient Chart Audit	Shirley Ju, MD
Physician Assessment of Patients' COVID-19 Risk and Impact on Lasmiditan, Ubrogepant, or Rimegepant Prescription Decisions: Analysis from a Cross-Sectional, Retrospective US Patient Chart Audit	Virginia Schobel, MSc



Retrospective Study of Intranasal Ketamine for Use in Patients with Refractory Headache	Hsiangkuo Yuan, MD, PhD
Pharmacokinetic and Pharmacodynamic Variability of Triptans. a Review and Some Clinical Implications*	
<i>*Not CME Eligible</i>	Peer Tfelt-Hansen, MD, DMSc
Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant – Post Hoc Results from an Open Label Safety Study (BHV3000-201)	Karissa Johnston, PhD
Rimegepant versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis	Evan Popoff, MSc
Acute Treatment with Rimegepant 75 Mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHV3000-201)*	
<i>*Not CME Eligible</i>	Lauren Powell, MPH
Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults with a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study	Ira Turner, MD
Rapid Decrease in Migraine Days with Rimegepant: Results from a Post Hoc Analysis of a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial*	
<i>*Not CME Eligible</i>	Richard Lipton, MD
Concordance of Response to Triptan with CGRP Monoclonal Antibody and Gepant: A Retrospective Review	Loretta Mueller, DO
Use of Memantine as a Preventative in Adolescents with Chronic Headache Disorders*	
<i>*Not CME Eligible</i>	Deanna Duggan, DNP
Gepant Efficacy When Combined with a CGRP Monoclonal Antibody: A Retrospective Chart Review	Loretta Mueller, DO
Acute Treatment with Oral Rimegepant 75 Mg Reduces Migraine-Related Disability in Adults with and Without a History of Triptan Treatment Failure: Results from a One Year, Open-Label Safety Study*	
<i>*Not CME Eligible</i>	Richard Lipton, MD
Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults with a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study	Ira Turner, MD
Occipital Nerve Blockade for the Treatment of Primary Headaches and Cranial Neuralgias*	
<i>*Not CME Eligible</i>	Luis Fernández-Garza
CGRP Monoclonal Antibodies Along with CGRP Receptor Antagonists Are Safe and Effective Together and Compared to Standard of Care	Amir Soheil Tolebeyan, MD
Safety and Efficacy of Repetitive Dihydroergotamine Infusion for the Acute Treatment of Refractory Chronic Migraine in Hospitalized Patients with Vascular Risk Factors	Clinton Lauritsen, DO
Treatment of Persistent Post-traumatic Headache with OnabotulinumtoxinA: Response Rates According to Clinical Phenotype*	
<i>*Not CME Eligible</i>	Allison Koutsandreas, CANP
Comparative Efficacy of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) versus Rizatriptan in the Acute Treatment of Migraine*	
<i>*Not CME Eligible</i>	Cedric O’Gorman, MD

Sustained, Clinically Meaningful Responses to Fremanezumab Treatment in Migraine Patients with Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications	Carrie Dougherty, MD, FAHS
Effects of Discontinuing Erenumab Treatment in Patients with High-frequency Episodic Migraine and Chronic Migraine: Experience of a Third-level Headache Center	Massimo Autunno
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses from 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed*	Richard Lipton, MD
<i>*Not CME Eligible</i>	
Treatment of Migraine Pain and Associated Symptoms with AXS-07: Results from MOVEMENT, a Long-term Efficacy and Safety Study*	Amanda Jones, PharmD
<i>*Not CME Eligible</i>	Stephanie Nahas, MD, MEd, FAHS
Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine over up to 15 Months	
No Evidence of Wearing off Effect for Fremanezumab Treatment in Chronic and Episodic Migraine Patients with Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications	Amaal Starling, MD
Real-world Reductions in Migraine and Headache Days After Initiating Fremanezumab for US Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway*	Maurice Driessen, PhD
<i>*Not CME Eligible</i>	
Reduced Nausea When Dihydroergotamine Mesylate Is Delivered by INP104*	Stephen Shrewsbury, MD
<i>*Not CME Eligible</i>	
DHE Pharmacology Revisited: Does a Broad Receptor Profile Molecule Treat the Whole Migraine?*	Sheena K Aurora, MD
<i>*Not CME Eligible</i>	
Combining Remote Electrical Neuromodulation (REN) with Guided Intervention of Education and Relaxation (GIER) in the Acute Treatment of Migraine	Dawn Buse, PhD
Efficacy of Lasmiditan for the Acute Treatment of Perimenstrual Migraine	E. Anne MacGregor, MBBS, MSc, MD, FFSRH
Comparison of Remote Electrical Neuromodulation (REN) and Standard-care Medications for Acute Treatment of Migraine in Adolescents: A Post-hoc Analysis	Andrew Hershey, MD, PhD, FAHS
Effects of Erenumab on Non-pain Symptoms in Patients with Chronic Migraine	Stewart Tepper, MD
Real Life Experience with Galcanezumab in a Single Tertiary Headache Center	Víctor Obach, MD
Neuroscience Education as Therapy for Migraine and Overlapping Pain Conditions*	Mia Minen, MD, MPH
<i>*Not CME Eligible</i>	
Long-term Use of Rimegepant 75 Mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics	David Kudrow, MD
Rimegepant 75 Mg for the Acute Treatment of Migraine in Adults with Frequent Migraine: Long-Term Safety and Clinical Improvement versus Baseline	Kathleen Mullin, MD
An Open-label, Intermediate-size, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine*	Robert Croop, MD
<i>*Not CME Eligible</i>	
Long-Term Safety of Rimegepant 75 Mg for the Acute Treatment of Migraine in Adults with a History of Triptan Treatment Failure	Kathleen Mullin, MD

Recurrence Rates for INP104 for the Acute Treatment of Migraine: Results from the Phase 3 STOP 301 Open-Label Study	Stewart Tepper, MD
Acute Treatment of Migraine with INP104: Exploratory Efficacy from the Phase 3 Open-Label STOP 301 Study*	
<i>*Not CME Eligible</i>	Sheena Aurora, MD
Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study*	
<i>*Not CME Eligible</i>	Stephen Shrewsbury, MD
Nasal Safety of Chronic Intermittent Use of INP104: Results from the Phase 3 Open-Label STOP 301 Study*	
<i>*Not CME Eligible</i>	Stephen Shrewsbury, MD
Treatment Consistency Across Multiple Migraine Attacks: Results from the Phase 3 Open-Label STOP 301 Study*	
<i>*Not CME Eligible</i>	Richard Lipton, MD
Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine*	
<i>*Not CME Eligible</i>	Todd Schwedt, MD
Reduction in Migraine-Associated Burden After Eptinezumab Treatment in Patients with Chronic Migraine	
Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days*	Peter McAllister, MD
<i>*Not CME Eligible</i>	
Evaluating the Utility of Patient-Identified Most Bothersome Symptom for Migraine Research	Lawrence Severt, MD, PhD
	Richard B. Lipton, MD
Efficacy and Safety of Erenumab in Patients with Episodic Migraine in East Asia: Taiwan and Korea Subpopulation Analysis of the EMPOwER Study	
Ubrogapant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain*	Shuu-Jiun Wang, MD
<i>*Not CME Eligible</i>	
Consecutive Headache-Free Days with OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: A Pooled PREEMPT Analysis*	Aubrey Manack Adams, PhD
<i>*Not CME Eligible</i>	
Real-World Evidence for Control of Chronic Migraine in Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA	Katherine Sommer, PhD
LasmiGepant: A Case Report of Simultaneous Administration of Lasmiditan and Rimegepant	Andrew Blumenfeld, MD
A Randomized Controlled Trial of High Rate rTMS versus rTMS and Amitriptyline in Chronic Migraine	Paul Mathew, MD, NDBPAS, FAHS
Analysis of Nutraceutical Medications for Migraine Prevention in a Pediatric and Adolescent Headache Clinic Population	Jayantee Kalita, DM
Selection Drivers for Recently Prescribed Lasmiditan, Ubrogapant, or Rimegepant for the Acute Treatment of Migraine: Results from an Annual Cross-Sectional Patient Chart Audit in the United States	Irene Patniyot, MD
Evaluation of the Correlations Between Pretreatment Plasma CGRP Levels, Disease Characteristics and Fremanezumab Treatment Response in Patients with Posttraumatic Headache*	Virginia Schobel, MSc
<i>*Not CME Eligible</i>	Jacki Rorabaugh, PhD

Patients with Migraine Who Achieved a $\geq 75\%$ Reduction in Monthly Migraine Days with Eptinezumab Treatment: Subgroup Analysis of PROMISE-1 and PROMISE-2*	Richard B. Lipton, MD
<i>*Not CME Eligible</i>	
Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2	Vincent Martin, MD
Efficacy and Safety of Eptinezumab in Patients with Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2*	Messoud Ashina, MD, PhD, DMSc
<i>*Not CME Eligible</i>	
Early Response to Eptinezumab Indicates High Likelihood of Continued Response with Treatment in Patients with Chronic Migraine*	Dawn Buse, PhD
<i>*Not CME Eligible</i>	
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients with Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2	Vincent Martin, MD
Changes in Blood Pressure Category with Erenumab: A Pooled Analysis of Phase 2 and Phase 3 Clinical Trials*	David Dodick, MD
<i>*Not CME Eligible</i>	
Daily Dosing of Atogepant for Preventive Treatment of Migraine Improved Patient-Reported Outcomes Measures of Migraine-Specific Quality of Life, Activity Impairment in Migraine-Diary, and Headache-Impact Test in a 52-Week Trial*	Pranav Gandhi, PhD
<i>*Not CME Eligible</i>	
Cardiovascular Safety of Eptinezumab: A Pooled Analysis of Double-Blind, Randomized, Placebo-Controlled Studies*	Timothy R. Smith, MD, RPh
<i>*Not CME Eligible</i>	
Evaluation of Ischemic Cardiovascular and Cerebrovascular Adverse Events by 10-year Cardiovascular Risk Score in Patients with Migraine Treated with Erenumab*	David Kudrow, MD
<i>*Not CME Eligible</i>	
Consistent Efficacy and Safety of Erenumab over Time in Patients with Episodic Migraine Who Completed a 5-year, Open-label Extension Study*	Messoud Ashina, MD, PhD, DMSc
<i>*Not CME Eligible</i>	
Utilization of Dihydroergotamine in Emergency Department and Infusion Center for Pediatric Migraine: A Retrospective Study	Ankita Ghosh, MD
Non-invasive Vagus Nerve Stimulation for Visual Snow*	Karissa Arca, MD
<i>*Not CME Eligible</i>	
Galcanezumab Effective for Chronic Refractory Cluster Headaches: A Case Report	Golshan Fahimi, MD
Real World Efficacy, Tolerability and Safety of Ubrogepant	Chia-Chun Chiang, MD
Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects*	Richard Bertz, PhD
<i>*Not CME Eligible</i>	
Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Randomized Active-controlled Double-dummy Trial*	Uwe Reuter, MD
<i>*Not CME Eligible</i>	
Improvement in Migraine Disability from Mindfulness is Mediated by Improvements in Pain Catastrophizing and Depression	Rebecca Wells, MD, MPH
Mechanisms of Mindfulness Through the Lens of Patient Voices: Results of a Qualitative Study	Rebecca Wells, MD, MPH

Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine\*

*\*Not CME Eligible*

Laszlo Mechtler, MD

Relative Efficacy of Lasmiditan versus Rimegepant and Ubrogapant as Acute Treatments of Migraine: Network Meta-Analysis Findings on Early Onset of Efficacy\*

*\*Not CME Eligible*

Pepa Polavieja, MSc